Your session is about to expire
← Back to Search
NXP800 for Advanced Cancers
Study Summary
This trial will test how safe different doses and schedules of NXP800 are.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had certain cancer treatments in the last 28-42 days.I am a woman who could become pregnant, or am currently pregnant or breastfeeding.I have severe side effects from past treatments.I am a man and will use contraception or abstain from sex to avoid fathering a child.I don't have severe side effects from past treatments, except for hair loss.You have a tumor that can be measured using the RECIST Version 1.1 guidelines.I am fully active or restricted in physically strenuous activity but can do light work.My cancer worsened within 6 months after finishing platinum-based treatment.I've had 1-3 cancer treatments, including one with bevacizumab.My ovarian cancer has an ARID1a mutation and is either clear cell or endometrioid type.My brain metastases have been stable for 12 weeks without steroids after treatment.I have a BRCA mutation and have been treated with a PARP inhibitor.My cancer is advanced, has spread, and there's no suitable treatment for me.I can take care of myself but might not be able to do heavy physical work.I can provide a tissue sample for the study, either already collected or by undergoing a biopsy.I am a woman who could become pregnant, am pregnant, or am breastfeeding.My cancer did not improve or got worse after first-line platinum chemotherapy.You have a measurable tumor according to specific guidelines for evaluating tumor size.I am 18 years old or older.I am 18 years old or older.I haven't had certain cancer treatments in the last 28-42 days.You are expected to live for at least 12 more weeks.My brain metastases have been stable for at least 28 days after treatment.
- Group 1: Part B: Expansion in Ovarian Cancers Cohort 2
- Group 2: Part A: Dose Escalation
- Group 3: Part B: Expansion in Ovarian Cancers Cohort 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an ongoing effort to enlist participants for this scientific experiment?
"This medical study is currently open for recruitment, with the initial post date being December 31st 2021 and final edit occurring August 9th 2022."
What are the inherent risks associated with NXP800 usage?
"Considering that NXP800 is in the first phase of trials, there is limited evidence to support its safety and efficacy. Thus, our team gave it a score of 1 on a scale from 1 to 3."
How many participants are taking part in this medical experiment?
"Affirmative. According to the data available on clinicaltrials.gov, this research project is currently in need of participants with 17 individuals being enrolled at a single location since its original posting date of December 31st 2021 and most recent update on August 9th 2022."
Share this study with friends
Copy Link
Messenger